Vital signs

U.S. DoD selects CCC, Thornhill Medical for critical care devices

Retrieved on: 
Thursday, January 11, 2024
CCC, Anesthesia, Oxygen, FAS, DLA, Armed, Ministry of Health, ERCS, USD, Vital signs, Nursing care plan, Ministry, USMC, Suction

Based in Toronto, Ontario, Thornhill Medical is a global innovator focused on respiratory and oxygen-related science and technology.

Key Points: 
  • Based in Toronto, Ontario, Thornhill Medical is a global innovator focused on respiratory and oxygen-related science and technology.
  • Marking its 20th year in 2024, Thornhill Medical is transforming the delivery of critical care and patient transport in austere and unpredictable combat casualty care, humanitarian and emergency environments.
  • Through its U.S. DoD Prime Contractor service, CCC partners with Canadian businesses like Thornhill Medical to supply the U.S. DoD with made in Canada solutions.
  • “We are pleased to contract with CCC to supply the U.S. DoD with our combat critical care technologies.

Providence Saint John's Health Center and Mahmee Partner to Expand Breastfeeding Services and Enhance Maternal Health Care

Retrieved on: 
Thursday, January 11, 2024
Women, Parenting, Children, Hospitals, Baby, Maternity, Health Technology, Family, General Health, Consumer, Health, Patient, Hospital, Mother, RN, Lactation, Partnership, Insurance, Consultant, FACS, IBCLC, RNC, Nursing, FACOG, MSN, Safety, Vital signs, Parent, MPH

Providence Saint John's Health Center is today announcing a partnership with Mahmee, a wraparound maternal healthcare company, to expand lactation care, enrich the postpartum experience and provide seamless support for new parents when they leave the hospital.

Key Points: 
  • Providence Saint John's Health Center is today announcing a partnership with Mahmee, a wraparound maternal healthcare company, to expand lactation care, enrich the postpartum experience and provide seamless support for new parents when they leave the hospital.
  • In the month following delivery, Providence Saint John’s patients will have access to a complimentary Mahmee membership.
  • By working with Mahmee, we are expanding our impact on families by offering essential support services, including mental health care and remote patient monitoring."
  • While Providence Saint John's has long championed maternal health care support, the partnership with Mahmee marks a monumental stride in creating a safety net during the most vulnerable phase of childbirth: the postpartum period.

NuraLogix Unveils Anura™ MagicMirror™ Creating New Possibilities for Health Measurement

Retrieved on: 
Tuesday, January 9, 2024
Transdermal optical imaging, Digital health, Patient, School, Mental health, Algorithm, Movement, Pharmacy, Vital signs, CES, Machine learning, Optical flow

LAS VEGAS, Jan. 9, 2024 /PRNewswire/ -- CES -- NuraLogix, a global pioneer in Affective Ai™1, is pleased to announce Anura™ MagicMirror™, a first-of-its-kind tabletop smart mirror that analyzes facial blood flow information to accurately calculate a host of vital signs and disease risk assessments. Powered by the company's cloud-based Affective Ai™ platform DeepAffex™, Anura™ MagicMirror™ is the first device NuraLogix has manufactured, leveraging its hardware-agnostic software to deliver on the promise of making accurate health data ubiquitous in people's lives.

Key Points: 
  • Powered by the company's cloud-based Affective Ai™ platform DeepAffex™, Anura™ MagicMirror™ is the first device NuraLogix has manufactured, leveraging its hardware-agnostic software to deliver on the promise of making accurate health data ubiquitous in people's lives.
  • A CES 2024 Innovation Award Honoree for Digital Health, Anura™ MagicMirror™ is being showcased at the NuraLogix booth #8917 in the North Hall throughout the CES show in Las Vegas.
  • Anura ™ MagicMirror™ is designed for conducting speedy and accurate physical and mental health assessments anywhere, anytime.
  • Uniquely, it can measure physical health vitals, as well as mental health assessments, and can carry out health risk assessments.

Movano Health and ams OSRAM Collaborate to Deliver Accurate Lifestyle Monitoring Solutions for Women

Retrieved on: 
Tuesday, January 9, 2024
Senior, CSA, Woman, SFH, OSRAM, Photoplethysmogram, PPG, Perfusion, Vital signs, Evie, Finger, Wearable computer, AMS, CES, AFE, Light, Light-emitting diode, Absorption, Ams-OSRAM, Optics

LAS VEGAS, Jan. 9, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, and ams OSRAM, a leader in technology for biometric monitoring, have collaborated to include ams OSRAMs PPG sensor solution in the Evie Ring, Movano Health's smart ring designed specifically for women.

Key Points: 
  • LAS VEGAS, Jan. 9, 2024 /PRNewswire/ -- Movano Health (Nasdaq: MOVE), a pioneer in health technology, and ams OSRAM, a leader in technology for biometric monitoring, have collaborated to include ams OSRAMs PPG sensor solution in the Evie Ring, Movano Health's smart ring designed specifically for women.
  • The ams OSRAM solution enables us to meet the unique needs of our consumer," said Michael Leabman, Founder and CTO of Movano Health.
  • "Our accurate optical sensors and advanced capabilities of our analog front end enable a miniaturized yet highly accurate PPG (Photoplethysmography) system.
  • Movano Health successfully launched the Evie Ring on November 20, 2023, and showcased the solution at CES Unveiled this past weekend.

5G in Defense Research Report 2023: Ultra-Reliable Low-Latency Communications (URLLC) - A Game Changer in 5G Defense

Retrieved on: 
Tuesday, January 9, 2024
Society, MEA, Government, NSA, Ultra, USD, NEC, Communication, Networking hardware, LTE, URLLC, Telecommunications, NTT Docomo, Internal affairs, L3Harris Technologies, Ligado Networks, SoftBank Group, SBA, Vital signs, Thales Group, VR, Health, C4ISR, 5G NR, Internet of things, Data-rate units, Artificial intelligence, Ministry, Intelligence, Nokia Networks, Architecture, Computer, Partnership, Unmanned aerial vehicle, 5G, Use, Raytheon Technologies, Torreón, Growth, MIC, KDDI, End user, Mobile phone

Due to a number of factors, the global market for 5G in defense are expanding significantly.

Key Points: 
  • Due to a number of factors, the global market for 5G in defense are expanding significantly.
  • The land 5G in Defense Market's growth is a reflection of the evolving strategic, operational, and technological landscapes of modern ground warfare.
  • Ultra-reliable and low-latency communications (URLLC): The Second largest share of the 5G in Defense Market by network type segment in 2023.
  • Ultra-reliable and low-latency communications (URLLC) is a service category supported by 5G in defense, which offers significant advantages for various industries and applications.

5G in Defense Research Report 2023 - Global Forecast to 2028: Increasing Use of 5G for IoT, Enhanced AR & VR, Advanced Autonomous Systems, and Cybersecurity to Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, January 8, 2024
Defense, Technology, Telecommunications, 5G, Networks, Other Defense, VR, Nokia Networks, URLLC, Computer, Architecture, Partnership, Health, Society, NTT Docomo, MEA, Government, Internal affairs, Unmanned aerial vehicle, L3Harris Technologies, NSA, Ultra, C4ISR, 5G NR, Ligado Networks, USD, NEC, Data-rate units, Artificial intelligence, Ministry, Raytheon Technologies, Torreón, Growth, Communication, Networking hardware, SoftBank Group, SBA, MIC, Intelligence, KDDI, Vital signs, Thales Group, End user, LTE, Mobile phone

Due to a number of factors, the global market for 5G in defense are expanding significantly.

Key Points: 
  • Due to a number of factors, the global market for 5G in defense are expanding significantly.
  • Faster data speeds and lower latency can support AR and VR applications for training simulations and on-the-battlefield data visualization.
  • The land 5G in Defense Market's growth is a reflection of the evolving strategic, operational, and technological landscapes of modern ground warfare.
  • Ultra-reliable and low-latency communications (URLLC): The Second largest share of the 5G in Defense Market by network type segment in 2023.

Owlet Transforms Infant Care with the Launch of Two FDA-Cleared Devices – Dream Sock® and BabySat™

Retrieved on: 
Monday, January 8, 2024
Women, Other Health, Parenting, Children, Telecommunications, Baby, Maternity, Software, Family, Medical Devices, Hospitals, Consumer, Data Management, Technology, Mobile, Wireless, General Health, FDA, Health, Apps, Applications, Entrepreneurship, Food, Caregiver, IOS, Mortality, Parent, Research, Babysitting, Insurance, Oxygen, Ventricular septal defect, OWLT, Sleep, Infant, Vital signs, De novo, Birth control

Owlet , Inc. (“Owlet” or the “Company”) (NYSE:OWLT), the pioneer of smart infant monitoring, today announces the launch and availability of Dream Sock® and BabySat™ , two medical devices with recent clearances from the U.S. Food and Drug Administration (“FDA”).

Key Points: 
  • Owlet , Inc. (“Owlet” or the “Company”) (NYSE:OWLT), the pioneer of smart infant monitoring, today announces the launch and availability of Dream Sock® and BabySat™ , two medical devices with recent clearances from the U.S. Food and Drug Administration (“FDA”).
  • Both innovations deliver real-time health insights with medical-grade accuracy and unprecedented advancements for at-home infant care.
  • These features are available to both existing and new Dream Sock users who opt to enable these features in the Dream App.
  • For more details on each device and to find out which product is the right choice for your family, visit www.owletcare.com .

Endotronix Submits PMA Application for its Cordella Pulmonary Artery Sensor System

Retrieved on: 
Friday, January 5, 2024
Cordella, Food, FDA, NYHA, News, IDE, GDMT, Congestion, Patient, HF, Heart failure, PMA, Vital signs, Pharmaceutical industry

NAPERVILLE, Ill., Jan. 5, 2024 /PRNewswire/ -- Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced the submission of a Premarket Approval (PMA) application for its Cordella™ Pulmonary Artery (PA) Sensor System to the U.S. Food and Drug Administration (FDA).

Key Points: 
  • NAPERVILLE, Ill., Jan. 5, 2024 /PRNewswire/ -- Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced the submission of a Premarket Approval (PMA) application for its Cordella™ Pulmonary Artery (PA) Sensor System to the U.S. Food and Drug Administration (FDA).
  • Cordella is an innovative HF patient management platform that delivers proactive PA pressure data and non-invasive vital health data for comprehensive heart failure management at home.
  • "Submitting this PMA application is a significant regulatory milestone and brings us one step closer to the expected commercial launch of the Cordella Sensor in the second half of this year."
  • This news follows the company's prior announcement that PROACTIVE-HF, the company's 450-patient investigational device exemption (IDE) trial, completed enrollment .

Endotronix Submits PMA Application for its Cordella Pulmonary Artery Sensor System

Retrieved on: 
Friday, January 5, 2024
Cordella, Food, FDA, NYHA, News, IDE, GDMT, Congestion, Patient, HF, Heart failure, PMA, Vital signs, Pharmaceutical industry

NAPERVILLE, Ill., Jan. 5, 2024 /PRNewswire/ -- Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced the submission of a Premarket Approval (PMA) application for its Cordella™ Pulmonary Artery (PA) Sensor System to the U.S. Food and Drug Administration (FDA).

Key Points: 
  • NAPERVILLE, Ill., Jan. 5, 2024 /PRNewswire/ -- Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced the submission of a Premarket Approval (PMA) application for its Cordella™ Pulmonary Artery (PA) Sensor System to the U.S. Food and Drug Administration (FDA).
  • Cordella is an innovative HF patient management platform that delivers proactive PA pressure data and non-invasive vital health data for comprehensive heart failure management at home.
  • "Submitting this PMA application is a significant regulatory milestone and brings us one step closer to the expected commercial launch of the Cordella Sensor in the second half of this year."
  • This news follows the company's prior announcement that PROACTIVE-HF, the company's 450-patient investigational device exemption (IDE) trial, completed enrollment .

Koneksa Announces New Multi-Domain Model for Functional Status Assessment Enabled by Digital Health Technologies

Retrieved on: 
Thursday, January 4, 2024
Data Management, Other Science, Practice Management, Physical Therapy, FDA, Technology, Research, Other Health, Surgery, Pharmaceutical, Oncology, Medical Devices, Hospitals, Genetics, Clinical Trials, Biotechnology, Software, Health, Science, Hardware, Continuity, Montefiore Medical Center, Influencer marketing, Clinical and Translational Science, PLOS, Informatics, Clinical trial, Cancer, Observational study, Elective surgery, JCO Clinical Cancer Informatics, Patient, Data collection, Protein, Vital signs, Area studies, Algorithm, Research fellow, Medical imaging

The paper, titled: “A Proposed Multi-Domain Digital Model for Capturing Functional Status and Health-Related Quality of Life in Oncology,” highlights the importance of collecting continuous 24/7 functional status measures digitally to enable better clinical decisions and outcomes assessment.

Key Points: 
  • The paper, titled: “A Proposed Multi-Domain Digital Model for Capturing Functional Status and Health-Related Quality of Life in Oncology,” highlights the importance of collecting continuous 24/7 functional status measures digitally to enable better clinical decisions and outcomes assessment.
  • However, the assessment of patients' functional status – encompassing physical, cognitive, and behavioral functioning – holds increasing significance in influencing clinical decisions and understanding treatment outcomes.
  • Koneksa's innovative digital model aims to address limitations in existing functional status assessments by leveraging digital health technologies (DHTs) for both objective and self-reported outcomes.
  • ”
    Continuous real-time digital monitoring of functional status can assess the health and well-being of patients in other diseases, such as in orthopedics.